Shares of Orgenesis Inc. (NASDAQ:ORGS – Free Report) are scheduled to reverse split before the market opens on Wednesday, September 25th. The 1-10 reverse split was announced on Monday, September 23rd. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, September 24th.
Orgenesis Price Performance
NASDAQ ORGS traded down $0.13 on Monday, reaching $0.39. 757,359 shares of the stock were exchanged, compared to its average volume of 180,954. Orgenesis has a one year low of $0.25 and a one year high of $1.08. The company’s 50-day simple moving average is $0.70 and its two-hundred day simple moving average is $0.63.
Orgenesis (NASDAQ:ORGS – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.23) EPS for the quarter. The business had revenue of $0.25 million for the quarter.
About Orgenesis
Orgenesis Inc, a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
See Also
- Five stocks we like better than Orgenesis
- Manufacturing Stocks Investing
- The Average 401k Balance by Age Explained
- Stock Market Upgrades: What Are They?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is Insider Trading? What You Can Learn from Insider Trading
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
